Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Renal pelvis and ureter cancer
Stage/Subtype:  metastatic transitional cell cancer of the renal pelvis and ureter
Trial Type:  Treatment
Results 1-25 of 36 for your search:
Start Over
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Not yet active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: ML29725, NCI-2015-01995, NCT02589717
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15679, NCI-2015-02085, 2014-003655-66, I4T-MC-JVDC, NCT02426125
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991001, NCI-2016-00304, 2015-003262-86, JAVELIN Bladder 100, NCT02603432
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
Ixazomib Citrate with Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0661, NCI-2015-00682, NCT02420847
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Radiation Therapy in Preventing Brain Metastases in Patients with Locally Advanced or Metastatic Bladder or Urinary Tract Cancer Previously Treated with Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2007-0933, NCI-2012-01675, NCT00756639
Tesetaxel for Previously Treated Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TOBL204, NCI-2011-02438, NCT01215877
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR105065, NCI-2015-00818, 2014-002408-26, 42756493BLC2001, NCT02365597
A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-126, NCI-2015-01786, NCT02553642
Cisplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor VX-970 in Treating Patients with Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9947, NCI-2015-01642, PHII-135, NCT02567409
Paclitaxel and Pembrolizumab in Treating Patients with Refractory Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 88215, NCI-2015-01713, NCT02581982
Pemetrexed Disodium in Treating Patients with Previously Treated Metastatic Urothelial Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0592, NCI-2016-00390, NCT02693717
A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 54828-201, NCI-2016-01513, NCT02872714
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B2151002, NCI-2013-01814, 2013-001390-24, NCT01920061
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AGS15E-13-1, NCI-2013-02093, NCT01963052
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASG-22CE-13-2, NCI-2014-01228, NCT02091999
Start Over